ChemoCentryx, Inc. is a biopharmaceutical company headquartered in Mountain View, California. Founded in 1997, it specialized in the discovery, development, and commercialization of orally administered small-molecule therapeutics targeting chemokine and chemoattractant receptors for the treatment of inflammatory diseases, autoimmune disorders, and cancer.
Its lead product, TAVNEOS (avacopan), is an oral complement C5a receptor inhibitor approved as an adjunctive therapy for adults with severe active ANCA-associated vasculitis. In October 2022, ChemoCentryx was acquired by Amgen for approximately $3.7 billion and now operates as a subsidiary, with its assets integrated into Amgen's portfolio.
